Estrella Immunopharma
ESLA
11 hedge funds and large institutions have $560K invested in Estrella Immunopharma in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 1 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0.06% more ownership
Funds ownership: 1.7% → 1.76% (+0.06%)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
2% less capital invested
Capital invested by funds: $568K → $560K (-$8.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$30.8K |
| 2 |
HF
HRT Financial
New York
|
+$16.7K |
| 3 |
BlackRock
New York
|
+$6.55K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.11K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$40.2K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.02K |
| 3 |
JP Morgan Chase
New York
|
-$21 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $242K | +$5.11K | +5,265 | +2% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $88.5K | +$3.07K | +3,164 | +3% |
|
|
3
UBS Group
Zurich,
Switzerland
| $69.9K | +$30.8K | +31,739 | +77% |
|
|
4
Citadel Advisors
Miami,
Florida
| $43K | -$40.2K | -41,443 | -45% |
|
|
ASM
5
ATW SPAC Management
New York
| $38.4K | – | – | – |
|
|
6
BlackRock
New York
| $30.2K | +$6.55K | +6,754 | +27% |
|
7
State Street
Boston,
Massachusetts
| $19.1K | – | – | – |
|
|
HF
8
HRT Financial
New York
| $14K | +$16.7K | +17,266 | New |
|
|
MCP
9
Maso Capital Partners
Hong Kong
| $9.6K | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $4.41K | -$1.02K | -1,053 | -19% |
|
11
Bank of America
Charlotte,
North Carolina
| $89 | +$5 | +5 | +6% |
|
|
12
JP Morgan Chase
New York
| – | -$21 | -23 | Closed |
|
ESLA Hedge Fund Activity: Q2 2025 in Review
11 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q2 2025, worth a combined $560K — down 1.6% from $568K a quarter earlier.
Fund positioning in ESLA was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, adding an estimated $30.8K. The largest seller was Citadel Advisors, cutting an estimated $40.2K.
- 11 institutional investors held Estrella Immunopharma (ESLA) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $560K of Estrella Immunopharma stock for Q2 2025, down 1.6% quarter-over-quarter.
- 1 fund opened new Estrella Immunopharma positions in Q2 2025 and 1 closed out, a net change of 0 holders.
- The largest Estrella Immunopharma buyer in Q2 2025 was UBS Group, an estimated $30.8K added.
- The largest Estrella Immunopharma seller in Q2 2025 was Citadel Advisors, an estimated $40.2K sold.
Based on aggregated 13F filings for Q2 2025.